ClinicalTrials.gg
CompletedNCT05878938FRONTIER 5Updated Dec 8, 2025

A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)

A Phase 3 interventional study of NNC0365-3769 (Mim8) PPX in Haemophilia A and Haemophilia A With Inhibitors, sponsored by Novo Nordisk A/S. Completed at 36 sites in 12 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-12-08.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jul 2024, 2 years 3 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Jul 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Not applicable
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 92 studies in Hemophilia A by Novo Nordisk A/S — 8 open to participants now, 12 under way, 5 of them phase 3. Hemophilia A · Novo Nordisk A/S.

Enrollment
22nd of 59
61 · median 38
Started
2023
with 2 others
Phase 3
21 of 92
1 open now
Registered
83rd of 92
by date

Among the 92 studies in Hemophilia A by Novo Nordisk A/S, this one is the 22nd largest by enrollment of the 59 interventional ones that give a count, is one of 3 that started in 2023, is one of 21 in phase 3, and was the 83rd registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

8 of the 92 studies in Hemophilia A by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 92 studies in Hemophilia A by Novo Nordisk A/S, or all of them as a file.
02

Study summary

This study is looking at how safe it is to switch from emicizumab to Mim8, in people with haemophilia A. Mim8 is a new medicine that is used to prevent bleeding episodes in people with haemophilia A. Mim8 works by replacing the function of the missing clotting factor VIII (FVIII). Mim8 will be injected under the skin using a pen-injector either once every week, once every two weeks or once every month. The participants will be trained in using the pen injector. The participants can choose themselves, in collaboration with the study doctor how often they get Mim8 in this study. When the participant will get their first Mim8 injection depends on their current treatment with emicizumab. The participants will get their first Mim8 injection at Visit 2. Participants will have between 6 and 27 Mim8 injections. The total number of injections participants will have depends on their dosing frequency. The study will last for about 6-12 months. While taking part in this study, there are some restrictions about what medicine participant can use. The study doctor will tell the participants more about this. In case the participants experience bleeds, these can be treated with additional haemostatic medicine as agreed with the study doctor. Female participants cannot take part if they are pregnant, breast-feeding or plan to get pregnant during the study period.

03

Conditions studied

  • Haemophilia A
  • Haemophilia A With Inhibitors

Browse trials for

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study, including activities to determine suitability for the study.
  2. Male or female with diagnosis of congenital haemophilia A of any severity based on medical records.
  3. Age 12 years or above at the time of signing the informed consent.
  4. Participants treated with emicizumab once-weekly (QW), once every two weeks (Q2W), or once every four weeks (Q4W) according to the label for at least 8 weeks prior to screening.
  5. Participants choosing to discontinue emicizumab treatment and switch to Mim8 QW, Q2W, or once-monthly (QM) treatment for 26 weeks from start of treatment (Visit 2).
  6. Participant and/or caregiver willingness and ability to comply with scheduled visits and study procedures, including the completion of an electronic diary and patient-reported outcomes (PRO) questionnaires.

Exclusion criteria

Exclusion Criteria:

  1. Participation (i.e., signed ) in any interventional, clinical study, with the exception of emicizumab, with receipt of the last dose within 8 weeks (or 5 half-lives of the medicinal product [IMP], whichever is longer) before screening.
  2. Any disorder, which in the investigator's opinion might jeopardise the participant's compliance with the protocol or safety, including ongoing Adverse Events (AEs) associated with emicizumab.
  3. Previous participation in this study. Participation is defined as signed informed consent.
  4. Known congenital or acquired coagulation disorders other than haemophilia A.
  5. Previous or current thromboembolic disease or events (with the exception of previous catheter associated thrombosis for which anti-thrombotic treatment is not currently ongoing) or risk of thromboembolic disease, as evaluated by investigator.
  6. Neutralising antibodies towards emicizumab have been detected or, for patients adherent to emicizumab therapy, are suspected based on clinical and laboratory assessments.
  7. Receipt of FVIII gene therapy at any time.
  8. Ongoing or planned immune tolerance induction therapy.
  9. Minor or major surgery planned to take place after screening and during the 26-week treatment period.
  10. Known or suspected to study intervention, related products, any constituents of the product or to other monoclonal antibodies.
  11. Hepatic dysfunction defined as (AST) and/or alanine aminotransferase (ALT) greater than (>) 3 times the upper limit combined with total >1.5 times the upper limit measured at screening.
  12. Renal impairment defined as estimated (eGFR) lesser than or equal to (≤) 30 milliliter per minute per 1.73 square meter (mL/min/1.73 m\^2) for serum creatinine measured at screening.
  13. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using highly effective method.
  14. Mental incapacity, unwillingness to cooperate, or a language barrier precluding adequate understanding and cooperation.
  15. Other conditions (e.g. disease) or laboratory abnormality that may increase risk of bleeding or thrombosis as evaluated by the investigator.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    NNC0365-3769 (Mim8) PPX

    Participants will receive Mim8 prophylaxis (PPX) subcutaneous (s.c.) injection using a prefilled fixed dose DV3407-C1 pen-injector.

    Drug: NNC0365-3769 (Mim8) PPX

Interventions

  • Participants will receive Mim8 PPX once-weekly dosing (QW), once every two weeks dosing (Q2W), or once-monthly dosing s.c. injection using a prefilled fixed dose DV3407-C1 pen-injector for 26 weeks.

06

What researchers measure

Primary outcomes

  1. Number of treatment-emergent adverse events

    Measured as count of events.

    Time frame: From Visit 2 (week 0) until week 26

Secondary outcomes

  1. Device handling experience using the Hemophilia Device Handling and Preference Assessment (HDHPA) questionnaire

    Measured as percentage of participants. HDHPA measures device handling experience and device preference. The measure consists of 26 items that are reported individually. it is measures in units: Percentage of participants = the distribution of participant answers within each response category, for each of the 26 individual items.

    Time frame: Visit 8 (after 26 weeks of treatment)

  2. Change in participants' treatment burden using the Hemophilia treatment experience measure (Hemo-TEM) total score

    Measured as score points. Hemo-TEM measures treatment burden. The measure consists of 26 items yielding 5 domain scores and 1 total score. Domain scores (score range): Injection difficulties (0-100), physical impact (0-100), treatment bother (0-100), interference with daily life (0-100), and emotional impact (0-100). Total score ranges 0-100. Higher scores indicate greater treatment burden.

    Time frame: From Visit 2 (week 0) until end of treatment (up to 26 weeks)

07

Study locations

36 sites
  • Children's Hospital Los Angeles - Endocrinology
    Los Angeles, California 90027, United States
  • UC Davis Medical Center
    Sacramento, California 95817, United States
  • UC Denver Hemoph & Thrombo Ctr
    Aurora, Colorado 80045, United States
  • St Joseph's Hospital Foundation
    Tampa, Florida 33607, United States
  • Augusta Univ/Childrens Hosp-GA
    Augusta, Georgia 30912, United States
  • Rush University Med. Cntr
    Chicago, Illinois 60612, United States
  • University of Iowa_Iowa City
    Iowa City, Iowa 52242, United States
  • Central Michigan University
    Detroit, Michigan 48201, United States
  • Michigan State University
    East Lansing, Michigan 48824, United States
  • Univ Hosp Cleveland Med Ctr
    Cleveland, Ohio 44106, United States
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
  • Penn State MS Hershey Med Ctr
    Hershey, Pennsylvania 17033-2360, United States
  • Vanderbilt U Med Ctr_Nashville
    Nashville, Tennessee 37212, United States
  • Universitätsklinik für Innere Medizin V
    Innsbruck, 6020, Austria
  • AKH - Klin. Abt. f. Haematologie u. Haemostaseologie
    Vienna, 1090, Austria
  • Cliniques universitaires Saint-Luc - Service Hématologie
    Brussels, 1200, Belgium
  • McMaster University
    Hamilton, Ontario L8N 3Z5, Canada
  • Hospices Civils de Lyon- Hopital Louis Pradel-1
    Bron, 69500, France
  • Vivantes Netzwerk für Gesundheit GmbH - Vivantes Klinikum im Friedrichshain
    Berlin, 10249, Germany
  • Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie
    Bonn, 53127, Germany
  • AOU Careggi Firenze
    Florence, Tuscany 50134, Italy
  • Fondazione IRCSS Ca' Granda Ospedale Maggiore Policlinico
    Milan, 20122, Italy
  • Azienda Ospedaliera di Rilievo Nazionale Santobono Pausilipon
    Naples, 80122, Italy
  • Azienda Ospedaliera Santobono Pausilipon - U.S.D. Centro Regionale Pediatrico Malattie della Coagulazione
    Naples, 80122, Italy
  • Nara Medical University Hospital_Pediatrics
    Nara, 634-8522, Japan
  • Charlotte Maxeke Johannesburg Academic Hospital
    Parktown, Johannesburg, Gauteng 2193, South Africa
  • Severance Hospital, Yonsei University Health System
    Seoul, 03722, South Korea
  • Kyung Hee University Hospital at Gangdong
    Seoul, 05278, South Korea
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
  • Hospital Regional Universitario de Málaga
    Málaga, 29010, Spain
  • Belfast City Hospital
    Belfast, BT9 78B, United Kingdom
  • Birmingham Children's Hospital
    Birmingham, United Kingdom
  • Arthur Bloom Haemophilia Centre
    Cardiff, CF14 4XW, United Kingdom
  • Royal Free Haemophilia Comprehensive Care Center
    London, NW3 2QG, United Kingdom
  • Royal Free Haemophilia Comprehensive Care Centre
    London, NW3 2QG, United Kingdom
  • Royal Hallamshire Hospital
    Sheffield, S10 2JF, United Kingdom
08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2023 to primary completion in Jul 2024, 12 months.

Of 89 industry-sponsored phase 3 interventional studies under Hemophilia A, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 56. This study's 12 months is below that.

Counting every sponsor, half of 91 studies reached it within 33 months; a quarter within 20 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2023
First posted
May 30, 2023
StartActual
Jun 26, 2023
Primary completionActual
Jul 18, 2024
CompletionActual
Jul 19, 2024
Results delay requested
Jul 18, 2025
Last update
Dec 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05878938
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
May 30, 2023
Start date
Jun 26, 2023
Primary completion
Jul 18, 2024
Completion
Jul 19, 2024
Last update
Dec 8, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denecimig

Start the discussion